VERTEX PHARMACEUTICALS INC / MA (VRTX) closed fiscal year 2025 with a gross margin of 86.2 % and a net margin of 32.9 %.
VERTEX PHARMACEUTICALS INC / MA (VRTX) closed fiscal year 2025 with a gross margin of 86.2 % and a net margin of 32.9 %. The same year shows an EBITDA margin of 36.5 % and an EBIT margin of 34.8 %. The free cash flow margin was 26.6 %. Against the previous year the gross margin moved +0.1 pp and the net margin +37.8 pp. Across the period the gross margin ranges between 84.5 % in 2012 and 100.0 % in 2010. The series covers 18 fiscal years, from 2008 to 2025. Margins are expressed as a percentage of net revenue and are derived from the same figures as the income statement, taken from as-reported SEC EDGAR filings, with no restatements or adjustments of our own.
Fiscal year end: December
| 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin (%) | — | — | 100.00 % | 95.49 % | 84.50 % | 92.66 % | 93.16 % | 88.65 % | 87.64 % | 88.95 % | 86.56 % | 86.84 % | 88.14 % | 88.06 % | 87.90 % | 87.21 % | 86.11 % | 86.24 % |
| EBITDA margin (%) | -245.30 % | -573.08 % | -464.27 % | 10.55 % | 5.56 % | -46.34 % | -108.40 % | -39.19 % | 4.19 % | 7.42 % | 23.22 % | 31.33 % | 47.79 % | 38.39 % | 49.89 % | 40.66 % | -0.23 % | 36.52 % |
| EBIT margin (%) | -263.65 % | -602.63 % | -485.51 % | 8.07 % | 3.06 % | -50.33 % | -119.30 % | -45.23 % | 0.58 % | 4.95 % | 20.84 % | 28.77 % | 46.03 % | 36.73 % | 48.23 % | 38.83 % | -2.11 % | 34.77 % |
| Net margin (%) | -262.02 % | -630.27 % | -526.35 % | 2.10 % | -7.01 % | -36.72 % | -127.25 % | -53.89 % | -6.58 % | 10.59 % | 68.80 % | 28.27 % | 43.70 % | 30.92 % | 37.20 % | 36.68 % | -4.86 % | 32.94 % |
| FCF margin (%) | -147.38 % | -442.72 % | -469.76 % | 7.74 % | 12.88 % | -9.25 % | -107.56 % | -39.79 % | 10.55 % | 29.96 % | 38.55 % | 35.89 % | 48.24 % | 31.80 % | 43.95 % | 33.81 % | -7.17 % | 26.61 % |
